Biota Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 82   

Articles published

BOTA 2.55 -0.02 (-0.78%)
price chart
Update: Biota Pharmaceuticals, Inc. Short Interest Grows by 0.9%
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), In a major negative the short interest in Biota Pharmaceuticals, Inc. shot up by 0.9% or 1,687 shares. The final shorts are 0.6% of the total floated shares. The positions increased from 190,660 shares on ...
Biota Pharmaceuticals to Acquire Anaconda Pharma
ATLANTA, Feb. 26, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals (Nasdaq:BOTA) (the "Company") announced today that it has entered into a definitive agreement to acquire Anaconda Pharma, a privately-held biotechnology company based in Paris, ...
Biota Pharmaceuticals, Inc. Files SEC Form SC 13G, Statement of Acquisition of ...
By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C. , by NewsRx journalists, a U.S.
Biota Pharmaceuticals: Recent Progress Illustrates Buying Opportunity Remains ...
While the termination of the BARDA contract in April 2014 that provided up $231 million for the development of laninamivir octanoate had a substantial negative effect on Biota in 2014 as it took away a source of major funding, the company has made ...
Biota Pharmaceuticals to Host Conference Call to Report Second Quarter Fiscal ...
ATLANTA, Jan. 29, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company"), a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening ...
Biota Pharmaceuticals Inc Stock Downgraded (BOTA)
The gross profit margin for BIOTA PHARMACEUTICALS INC is currently lower than what is desirable, coming in at 34.92%. It has decreased significantly from the same period last year.
Related articles »  
Biota Pharmaceuticals (BOTA) Upgraded From Sell to Hold
"We rate BIOTA PHARMACEUTICALS INC (BOTA) a HOLD. The primary factors that have impacted our rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative ...
Biota Pharmaceuticals Stock Rating Upgraded by TheStreet (BOTA)  The Legacy
Biota Pharmaceuticals Upgraded to Hold at TheStreet (BOTA)  Ticker Report
Biota Pharmaceuticals relos HQ to Atlanta
Rockville, Md.-based Biota Pharmaceuticals, Inc. [NASDAQ: BOTA] focuses on the development of anti-infective products to prevent and treat potentially life-threatening viral and bacterial infectious diseases, such as respiratory syncytial virus disease ...
Biota Pharmaceuticals to Make Alpharetta, GA Its New Home  GPB (blog)
Related articles »  
Biota Pharmaceuticals Reports Second Quarter Fiscal Year 2015 Financial Results
ATLANTA, Feb. 5, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company") today announced its financial results for the three month period ended December 31, 2014, which is the second quarter of the Company's 2015 ...
The Street Rating Update on Biota Pharmaceuticals Inc
Biota Pharmaceuticals Inc (NASDAQ:BOTA), The Street has revised its outlook on the counter according to the recent research report.
Stocks in news: Xencor (NASDAQ:XNCR), Biota Pharmaceuticals (NASDAQ ...  Property Mentor